Samanta Lalic1,2, Natasa Gisev3, J Simon Bell1, Maarit Jaana Korhonen1, Jenni Ilomäki1. 1. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia. 2. Pharmacy Department, Austin Health, Melbourne, Australia. 3. National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia.
Abstract
AIMS: To identify patterns of opioid analgesic use and determine predictors of persistent opioid use among people without cancer. METHODS: A population-based cohort study of Australians initiating prescription opioids from July 2013 to December 2015 was conducted using data from a random 10% sample of people who accessed medicines through Australia's Pharmaceutical Benefits Scheme. A 12-month retrospective period was used to define opioid initiation, exclude people with cancer and determine comorbidities. Persistent use over 12 months since initiation was identified through group-based trajectory modelling. Odds ratios (OR) and 95% confidence intervals (CIs) for predictors of opioid persistence were estimated using logistic regression. RESULTS: The cohort consisted of 431 963 people without cancer who initiated opioids. A total of 11 323 (2.6%) persistent opioid users were identified. Predictors of persistence included initiation with transdermal formulations (OR 4.2, 95% CI 3.9-4.5), or initiation with total oral morphine equivalents (OME) ≥ 750 mg (3.7, 3.3-4.1), having depression (1.6, 1.5-1.7) or psychotic illness (2.0, 1.9-2.2). Previous dispensing of paracetamol (2.0, 1.9-2.1), pregabalin (2.0, 1.8-2.1) and benzodiazepines (1.53, 1.4-1.6) predicted persistence. Compared to people aged 18-44 years, those ≥75 years were 2.5 (2.3-2.6) times more likely to be persistent users. CONCLUSIONS: Patient-specific characteristics (older age, prior history of mental health comorbidities and use of non-opioid analgesics) and prescriber choice of initial opioid (transdermal formulation and higher total OMEs) were found to strongly predict persistent use. This information may help prescribers target monitoring and early intervention efforts in order to prevent harms associated with the long-term use of opioids.
AIMS: To identify patterns of opioid analgesic use and determine predictors of persistent opioid use among people without cancer. METHODS: A population-based cohort study of Australians initiating prescription opioids from July 2013 to December 2015 was conducted using data from a random 10% sample of people who accessed medicines through Australia's Pharmaceutical Benefits Scheme. A 12-month retrospective period was used to define opioid initiation, exclude people with cancer and determine comorbidities. Persistent use over 12 months since initiation was identified through group-based trajectory modelling. Odds ratios (OR) and 95% confidence intervals (CIs) for predictors of opioid persistence were estimated using logistic regression. RESULTS: The cohort consisted of 431 963 people without cancer who initiated opioids. A total of 11 323 (2.6%) persistent opioid users were identified. Predictors of persistence included initiation with transdermal formulations (OR 4.2, 95% CI 3.9-4.5), or initiation with total oral morphine equivalents (OME) ≥ 750 mg (3.7, 3.3-4.1), having depression (1.6, 1.5-1.7) or psychotic illness (2.0, 1.9-2.2). Previous dispensing of paracetamol (2.0, 1.9-2.1), pregabalin (2.0, 1.8-2.1) and benzodiazepines (1.53, 1.4-1.6) predicted persistence. Compared to people aged 18-44 years, those ≥75 years were 2.5 (2.3-2.6) times more likely to be persistent users. CONCLUSIONS:Patient-specific characteristics (older age, prior history of mental health comorbidities and use of non-opioid analgesics) and prescriber choice of initial opioid (transdermal formulation and higher total OMEs) were found to strongly predict persistent use. This information may help prescribers target monitoring and early intervention efforts in order to prevent harms associated with the long-term use of opioids.
Authors: Jennifer L Pilgrim; Sabrina Putrianita Yafistham; Sanjeev Gaya; Eva Saar; Olaf H Drummer Journal: Forensic Sci Med Pathol Date: 2014-11-18 Impact factor: 2.007
Authors: Roxanne Schaakxs; Hannie C Comijs; Roos C van der Mast; Robert A Schoevers; Aartjan T F Beekman; Brenda W J H Penninx Journal: Am J Geriatr Psychiatry Date: 2017-04-07 Impact factor: 4.105
Authors: Maria C S Inacio; Craig Hansen; Nicole L Pratt; Stephen E Graves; Elizabeth E Roughead Journal: BMJ Open Date: 2016-04-29 Impact factor: 2.692
Authors: Richard Ofori-Asenso; Jenni Ilomäki; Mark Tacey; Si Si; Andrea J Curtis; Ella Zomer; J Simon Bell; Sophia Zoungas; Danny Liew Journal: Br J Clin Pharmacol Date: 2018-11-08 Impact factor: 4.335
Authors: Kate N Wang; J Simon Bell; Edwin C K Tan; Julia F M Gilmartin-Thomas; Michael J Dooley; Jenni Ilomäki Journal: Drugs Aging Date: 2019-11 Impact factor: 3.923
Authors: Nathan N O'Hara; Andrew N Pollak; Christopher J Welsh; Lyndsay M O'Hara; Alyson K Kwok; Alexandra Herman; Gerard P Slobogean Journal: JAMA Netw Open Date: 2018-10-05